Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus

A meta-analysis

Jian Li, MD\textsuperscript{a}, Yanping Gong, MD\textsuperscript{a}, Chunlin Li, MD\textsuperscript{a}, Yanhui Lu, MD\textsuperscript{a}, Yu Liu, MD\textsuperscript{a}, Yinghong Shao, MD\textsuperscript{b,1}\textsuperscript{*}

Abstract
Background: Drug intensification is often required for patients with type 2 diabetes mellitus on stable metformin therapy. Among the potential candidates for a combination therapy, sodium-glucose transporter-2 (SGLT2) inhibitors have shown promising outcomes. This meta-analysis was performed to compare the efficacy and safety of SGLT2 inhibitors with non-SGLT2 combinations as add-on treatment to metformin.

Methods: Literature search was carried out in multiple electronic databases for the acquisition of relevant randomized controlled trials (RCTs) by following a priori eligibility criteria. After the assessment of quality of the included RCTs, meta-analyses of mean differences or odds ratios (OR) were performed to achieve overall effect sizes of the changes from baseline in selected efficacy and safety endpoints reported in the individual studies. Between-studies heterogeneity was estimated with between-studies statistical heterogeneity (I\textsuperscript{2}) index.

Results: Six RCTs fulfilled the eligibility criteria. SGLT2 inhibitors as add-on to metformin treatment reduced \% HbA1c significantly more than non-SGLT2 combinations after 52 weeks (P = .002) as well as after 104 weeks (P < .00001). Among other endpoints, SGLT2 inhibitors also reduced fasting plasma glucose levels, body weight, systolic, and diastolic blood pressures after 52 weeks and 104 weeks significantly (P < .00001) more than non-SGLT2 combinations. Incidence of hypoglycemia was significantly lower (P = .02) but incidence of suspected or confirmed genital tract infections was significantly higher (P < .00001) in SGLT2 inhibitors treated in comparison with non-SGLT2 combinations.

Conclusion: As add-on to metformin treatment, SGLT2 inhibitors are found significantly more efficacious than non-SGLT2 inhibitor combinations in the management of type 2 diabetes mellitus, although, SGLT2 inhibitor therapy is associated with significantly higher incidence of suspected or confirmed genital tract infections.

Abbreviations: AE = adverse effect, BW = body weight, CANA = canagliflozin, chol = cholesterol, DAPA = dapagliflozin, DBP = diastolic blood pressure, DPP-4 = dipeptidyl peptidase-4, eGFR = estimated glomerular filtration rate, EMPA = FDA = Federal Drug Agency, empagliflozin, FPG = fasting plasma glucose, GLP-1 = glucagon-like peptide 1, HbA1c = glycosylated hemoglobin-A1c, HDL = high density lipoprotein, F = between-studies statistical heterogeneity, IPRA = ipragliflozin, kcal = kilocalories, LDL = low-density lipoprotein, MeSH = medical subject headings, mg = milligram, OR = odds ratio, PPG = postprandial glucose, PRISMA = preferred reporting items for systematic reviews and meta-analyses, RCT = randomized controlled trial, SAT = subcutaneous adipose tissue, SBP = systolic blood pressure, SGLT = sodium-glucose cotransporter, TOFO = tofogliflozin, VAT = visceral adipose tissue.

Keywords: meta-analysis, metformin, SGLT2 inhibitor, sodium-glucose cotransporter-2 inhibitor, type 2 diabetes

Editor: Jinxian Xu.

JL and YG have contributed equally to this work.

The authors report no conflicts of interest.

\textsuperscript{a} Department of Geriatric Endocrinology, \textsuperscript{b} Outpatient Department, Chinese PLA General Hospital, Beijing 100853, China.

Correspondence: Yinghong Shao, Outpatient Department, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (e-mail: shaoyh_med@163.com).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2017) 96(27):e7201

Received: 17 May 2016 / Received in final form: 17 May 2017 / Accepted: 21 May 2017

1. Introduction

Type 2 diabetes mellitus is one of the most prevalent and devastating diseases with a global incidence estimate of about 9% of adult population. According to an estimate, in the year 2012 alone, this disease caused 1.5 million deaths.\textsuperscript{[1]} This form of metabolic disorder poses increased risk of morbidity and mortality attributable to a reduced life expectancy of up to 13 years.\textsuperscript{[2]} Among several pathologies associated with type 2 diabetes mellitus, microvascular complications can cause blindness, renal failure, and the loss of function of other important organs.\textsuperscript{[3]} Cerebrovascular and cardiovascular morbidity related mortality risk is 2 to 4 times higher in type 2 diabetes mellitus patients than in general population.\textsuperscript{[4]}

Upon diagnosis, if lifestyle interventions remain insufficient to control type 2 diabetes, metformin is the first line drug. Metformin is an efficacious drug because of its glycemic control, insulin sensitizing, and body weight effects.\textsuperscript{[5]} However, with the
passage of time it may not provide adequate glycemic control due to disease progression which necessitates add-on treatments to maintain euglycemia which is necessary for the prevention of glucotoxicity. According to the American Diabetes Association and the American Association of Clinical Endocrinologists guidelines, metformin may be followed by GLP-1 receptor agonists, DPP-4 inhibitors, or SGLT2 inhibitors in preference to sulfonylurea, thiazolidinediones, meglitinitides, alpha-glycosidase inhibitors, bile acid sequestrants, dopamine-2 agonists, amylin mimetics, or insulin. However, depending on the level of HbA1c lowering requirements, associated risk of medication and tolerability properties of a particular drug, preferences can be modified.[6,7]

Among the recently developed drugs, SGLT2 inhibitors have also shown promising results for type 2 diabetes patients.[8-10] Selective and reversible inhibition of SGLT2 can lower blood glucose levels independent of insulin status and is also found to manifest favorable effects on hypertension and body weight control, besides maintaining glycemic control. The SGLT2 is a high-capacity and low-affinity protein, which is expressed in abundance in the proximal renal tubules where it reabsorbs 80% to 90% of glucose. It should be distinguished from the SGLT1 which is low-capacity and high-affinity protein expressed mainly in the small intestine and late proximal renal tubules and is more important for intestinal absorption of glucose and galactose.[11-13]

Among the notable SGLT2 inhibitor drugs, dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, and luseogliflozin are well-studied for their efficacy, safety, tolerability, bioavailability, pharmacokinetic, and pharmacodynamic properties.[9,10]

In a number of clinical studies with type 2 diabetes patients, SGLT2 inhibitors are found to decrease HbA1c, fasting plasma glucose (FPG) levels, and body weight by inducing favorable glucosuria (urinary loss of approximately 200–300 kcal/d) in a variety of designs involving monotherapies and combination therapies.[14-19] Whereas, a recent meta-analysis of the placebo-controlled RCTs has found SGLT2 inhibitors efficacious as add-on to metformin treatment,[20] there is no study to systematically review the efficacy and safety of SGLT2 inhibitors against non-SGLT2 combinations investigated in RCTs. Aim of the present study was to evaluate the efficacy and safety of this important therapeutic regimen by performing a meta-analysis of the RCTs which compared the efficacy and safety of SGLT2 inhibitors against non-SGLT2 combinations, as add-on to metformin treatment for more than 1-year.

2. Methods

This meta-analysis was performed by following Cochrane Collaboration guidelines and is reported in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. Ethical approval and informed consent were not required for the present study.

2.1. Literature search

The literature search was carried out in Medline/PubMed, Embase, Scopus, Ovid SP, Google Scholar, and Web of Science databases. The MeSH and keywords used in different combinations were sodium-glucose cotransporter-2 inhibitor, SGLT2 inhibitor, dapagliflozin, DAPA, canagliflozin, CANA, ipragliflozin IPRA, empagliflozin, EMPA, tofogliflozin, TOFO, luseogliflozin, type 2 diabetes mellitus, randomized controlled trial, RCT, efficacy, safety, tolerability, adverse effects, AEs, metformin, add-on treatment, glycosylated hemoglobin, HbA1c, fasting plasma glucose, FPG, systolic blood pressure, SBP, diastolic blood pressure, DBP, body weight, postprandial glucose, PPG, cholesterol, high density lipoprotein, HDL, low-density lipoprotein, LDL, triglyceride, and estimated glomerular filtration rate, eGFR. Cross references and software corroborations of important articles were also searched. The search encompassed original articles published before September 2016.

2.2. Primary and secondary endpoints

Studies included in the meta-analyses are RCTs which evaluated the efficacy, safety, and tolerability of a SGLT2 inhibitor as add-on to metformin by comparing with a suitable non-SGLT2 combination. Participants were type 2 diabetes patients having inadequate control of disease by diet/exercise and metformin therapy. Primary outcome measures of interest were the changes from baseline in percent HbA1c, FPG levels, and body weight. Secondary endpoints were the changes from baseline in blood pressure (SBP and DBP), lipid profile (HDL-cholesterol, LDL-cholesterol, and triglyceride), and eGFR. Safety endpoints were the incidence of hypoglycemia, incidence of genital tract infections, incidence of urinary tract infections, and incidence of ketoacidosis.

2.3. Inclusion and exclusion criteria

The inclusion criteria were: (a) RCT recruited adult type 2 diabetes patients to evaluate the efficacy and safety of a SGLT2 inhibitor as add-on to metformin treatment by comparing it with a suitable non-SGLT2 combination controlled group; and (b) trial reported at least 1 indicator of disease condition of interest (primary, secondary and/or safety). Exclusion criteria were: Relevant RCTs (a) of less than 52 weeks duration, (b) examined the efficacy of SGLT2 inhibitors as add-on to metformin against a placebo-controlled group or as a single arm study, (c) compared SGLT2 inhibitor monotherapy with metformin either alone or in combination with other antidiabetic drugs, (d) compared SGLT2 inhibitors in combination with other non-SGLT2 drugs with any other combination or monotherapy as add-on to metformin, and (e) report provided inadequate information about quantitative outcomes.

2.4. Quality assessment of the trials

Quality assessment of the RCTs included in this meta-analysis was carried out by using the Cochrane Collaboration’s (St Albans House, London, UK) Tool for Quality Assessment of Randomized Controlled Trials.[21]

2.5. Data extraction, synthesis and statistical analysis

Data extraction was carried out by 2 reviewers independently by adapting a standardized procedure. Data pertaining to the participants’ demographic and pathological characteristics, intervention design, and trial eligibility criteria, outcome measures, and outcomes were extracted from the selected research articles. From the studies which used multiple doses of a SGLT2 inhibitor drug, dose groups were selected to achieve maximum equivalence between the studies. Changes from baseline in the endpoints were either extracted raw from the respective research articles if provided, or calculated from the baseline values and values noted at weeks 24, 52, and 104 of treatment duration. Data and analyses module of RevMan software (version 5.2; Cochrane Collaboration) was used for the
meta-analyses of weighted mean differences (for efficacy endpoints) or OR (for safety endpoints) between SGLT2 inhibitors and non-SGLT2 combinations. Between-studies inconsistency (heterogeneity) was tested by $I^2$ statistics.

3. Results

Six RCTs\(^{[22–27]}\) out of 17 related trials which were screened from 116 abstracts fulfilled the eligibility criteria (Fig. 1). Placebo-controlled trials, trials investigating SGLT2 inhibitor plus non-SGLT2 inhibitor as add-on to metformin designs, monotherapy in 1 arm (SGLT2 inhibitor as add-on to metformin vs monotherapy) designs, and pharmacokinetic/pharmacodynamics studies were excluded. Important characteristics of the included studies are presented in Tables 1 and 2. Quality of the included studies was generally high. An assessment summary is presented in Table 3.

Overall, this meta-analysis is based on 4533 type 2 diabetes patients with inadequate control on the disease with lifestyle interventions and metformin despite a daily dose range of 1.5 to 3 g. Of these, 2320 patients were treated with a SGLT2 inhibitor (CANA/DAPA/EMPA) and 2213 were treated with a non-SGLT2 combination (glimepiride/linagliptin/sitagliptin/glipizide), as add-on to metformin. All of these trials used percent change in HbA1c levels from baseline as the primary endpoint. Secondary and exploratory endpoints included changes from baseline in FPG,

---

**Table 1** Study design characteristics of the studies/study arms included in the meta-analysis.

| Study                  | Trial identifier | Trial duration (wk) | Number of patients | SGLT-Inh | Non-SGLT-Inh | Dosage |
|------------------------|------------------|---------------------|--------------------|----------|--------------|--------|
| Cefalu et al\(^{[22]}\)/Leiter et al (2015) | NCT00968812      | 104                 | 485 CANA 482 Glimepride | SGLT-Inh | Non-SGLT-Inh | MET |
| DeFronzo et al (2014)  | NCT01422876      | 52                  | 140 EMPA 128 LINA  | EMPA 25 mg/d | LINA 5 mg/d | ≥1.5 g/d |
| Ferrannini et al\(^{[24]}\) | NCT00881530  | 90+                 | 166 EMPA 56 SITA  | EMPA (25 mg/d) | SITA (100 mg/d) | ≥1.5 g/d |
| Lavalle-Gonzalez et al. (2013) | NCT01106677    | 52                  | 367 CANA 366 SITA  | CANA (300 mg/d) | SITA (100 mg/d) | ≥2 g/d |
| Nauck et al\(^{[26]}\)/Nauck et al (2013) | NCT00660007  | 52                  | 400 DAPA 401 Glipizide | DAPA (up-titrated) | Glipizide (up-titrated) | 2 g/d |
| Ridderstrale et al\(^{[27]}\) | NCT01167881     | 104                 | 765 EMPA 780 glimepride | EMPA (25 mg/d) | Glimepride (1–4 mg/d) | ≥1.5 g/d |

CANA = canagliflozin, DAPA = dapagliflozin, EMPA = empagliflozin.
Table 2
Patient characteristics of the included studies.

| Study          | Age (y) | Males | BMI (kg/m²) | Disease length (y) | HbA1c (%) | FPG (mM/L) | SBP (mm Hg) | DBP (mm Hg) | TG (mmol/L) | LDL-chol (mmol/L) | HDL-chol (mmol/L) | eGFR (mL/min/1.73m²) |
|----------------|---------|-------|-------------|-------------------|-----------|------------|-------------|-------------|-------------|-------------------|------------------|-------------------|
| Cefalu et al (2013) | 56.2 ± 9.2 | 52%   | 31 ± 5.4    | 6.6 ± 5.3         | 7.8 ± 0.8 | 9.2 ± 2.1 | 130 ± 13.1  | 79 ± 8.2    | 2 ± 1.6     | 2.8 ± 0.9         | 1.2 ± 0.3         | –                 |
| DeFronzo et al (2014) | 55.8 ± 10.2 | 50%   | 30.2 ± 5.3  | 5–5 y, 43.8% over 5–5 y, 55.9% | 8.02 ± 0.83 | 8.8 ± 2.1 | 129.2 ± 13.4 | 79.9 ± 8.7  | 2 ± 0.15  | 2.7 ± 0.1         | 1.2 ± 0  | 90.2 ± 19         |
| Ferrannini et al (2013) | 56.2 ± 9.2 | 52%   | 30.2 (20–40) | 1–5 y 38% and >5 y 54% | 7.94 ± 0.8 | 9.9 ± 2.2 | 136.5 ± 14.6 | 80.9 ± 9.4  | 2.2 ± 2.3 | 2.7 ± 0.9         | 1.3 ± 0.3         | 92.2 ± 19         |
| Lavalle-Gonzalez et al (2013) | 55.4 ± 9.4 | 47.1%  | 35.1 ± 5.5  | 6.5 ± 5.5         | 7.8 ± 0.9 | 10.7 ± 3.2 | 21 ± 1.3    | 2.8 ± 0.9    | 1.2 ± 0.3   | 89.4              |
| Nauck et al (2013) | 58.5 ± 9.5 | 55.1%  | 31.5 ± 5.5  | 6.5 ± 5.5         | 7.7 ± 0.9 | 9.0 ± 2.2 | 1.9 ± 1.4  | 2.6 ± 1.9    | 1.19 ± 0.22 | 90.5 ± 19         |

BMI = body mass index, chol = cholesterol, eGFR = estimated glomerular filtration rate, FPG = fasting plasma glucose, HbA1c = glycated hemoglobin A1c, HDL = high-density lipoprotein, LDL = low-density lipoprotein, SBP = systolic/diastolic blood pressure, TG = triglycerides.

Table 3
Risk of bias assessment in the included studies.

| Study          | Other bias reporting | Selective outcome data | Incomplete outcome data | Blinding of outcome assessment | Blinding of participants/personnel | Allocation concealment | Random sequence generator |
|----------------|----------------------|------------------------|-------------------------|-------------------------------|-----------------------------------|------------------------|---------------------------|
| Cefalu et al (2013) | 2                   | 1                      | 1                       | L                             | L                                 | L                       | L                         |
| DeFronzo et al (2014) | 2                   | 2                      | 2                       | L                             | L                                 | L                       | L                         |
| Ferrannini et al (2013) | 2                   | 2                      | 2                       | L                             | L                                 | L                       | L                         |
| Lavalle-Gonzalez et al (2013) | 2                   | 2                      | 2                       | L                             | L                                 | L                       | L                         |
| Nauck et al (2013) | 2                   | 2                      | 2                       | L                             | L                                 | L                       | L                         |
| Riddlerstrahl et al (2013) | 2                   | 2                      | 2                       | L                             | L                                 | L                       | L                         |

H = high risk, L = low risk, U = unclear risk.

PPG, BW, SBP, DBP, percent patients with HbA1c < 7%, and hypoglycemia incidence. Major findings of the meta-analysis are given in Table 4. The SGLT2 inhibitors as add-on to metformin treatment were found to be associated with significantly better efficacy in comparison with non-SGLT2 combinations for at least up to 2 years of treatment. Improvement in the change from baseline in %HbA1c was significantly more in SGLT2 inhibitors than in non-SGLT2.

Table 4
Major findings of the meta-analysis of 52-week trials with findings of 1 104-week trials.

| Parameter/Duration | No. of RCTs | No. of participants | Mean difference [95% CI] | Significance level | Heterogeneity (I²) |
|--------------------|-------------|---------------------|--------------------------|--------------------|---------------------|
| HbA1c (%)          |             |                     |                          |                    |                     |
| After 24 weeks     | 6           | 4489                | −0.00 [−0.02, 0.11]      | P = .22            | 90%                 |
| After 52 weeks     | 6           | 4507                | −0.11 [−0.18, −0.04]     | P < .0001          | 54%                 |
| After 104 weeks    | 3           | 2707                | −0.16 [−0.21, −0.08]     | P < .00001         | 22%                 |
| FPG                |             |                     |                          |                    |                     |
| After 24 weeks     | 2           | 1142                | −0.65 [−1.34, 0.04]      | P = .06            | 80%                 |
| After 52 weeks     | 5           | 4188                | −0.65 [−0.94, −0.35]     | P < .0001          | 84%                 |
| After 104 weeks    | 3           | 2707                | −0.72 [−0.86, −0.58]     | P < .00001         | 0%                  |
| Body weight        |             |                     |                          |                    |                     |
| After 24 weeks     | 5           | 3274                | −3.98 [−4.68, −3.28]     | P < .00001         | 82%                 |
| After 52 weeks     | 6           | 4147                | −3.87 [−4.94, −2.80]     | P < .00001         | 95%                 |
| After 104 weeks    | 3           | 2707                | −3.53 [−4.86, −2.21]     | P < .00001         | 92%                 |
| SBP                |             |                     |                          |                    |                     |
| After 24 weeks     | 1           | 1545                | −5.60 [−6.91, −4.29]     | P < .0001          | –                   |
| After 52 weeks     | 5           | 4276                | −4.88 [−5.66, −4.10]     | P < .00001         | 23%                 |
| After 104 weeks    | 3           | 2707                | −5.33 [−6.29, −4.38]     | P < .00001         | 0%                  |
| DBP                |             |                     |                          |                    |                     |
| After 24 weeks     | 1           | 1545                | −2.40 [−3.50, −1.30]     | P < .00001         | 0%                  |
| After 52 weeks     | 4           | 4008                | −2.38 [−2.93, −1.84]     | P < .00001         | 62%                 |
| After 104 weeks    | 3           | 2707                | −2.55 [−3.19, −1.91]     | P < .00001         | 0%                  |
| eGFR               |             |                     |                          |                    |                     |
| After 24 weeks     | 2           | 1064                | 2.32 [−0.14, 4.76]       | P = .06            | 34%                 |
| After 52 weeks     | 4           | 2139                | 3.43 [1.65, 5.21]        | P = .00002         | 77%                 |
| After 104 weeks    | 2           | 1051                | 0.26 [−6.12, 6.63]       | P = .94            | 80%                 |
| LDL cholesterol (%) change | | | | | |
| After 24 weeks | 1 | 970 | 9.00 [3.47, 14.53] | P = .001 | – |
| After 52 weeks | 3 | 2449 | 2.47 [0.25, 4.68] | P = .03 | 99% |
| After 104 weeks | 1 | 967 | 8.00 [2.07, 13.93] | P = .008 | – |
| HDL cholesterol (%) change | | | | | |
| After 24 weeks | 1 | 967 | 7.50 [4.87, 10.13] | P < .0001 | – |
| After 52 weeks | 3 | 2449 | 6.89 [5.82, 7.98] | P < .0001 | 97% |
| After 104 weeks | 1 | 967 | 9.30 [6.65, 11.95] | P < .0001 | – |

Dose regimen: EMPA (25 mg/d), CANA (300 mg/d), and DAPA (up-titrated 2.5 to 10 mg/day). DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FPG = fasting plasma glucose, HbA1c = glycated hemoglobin A1c, HDL = high-density lipoprotein, LDL = low-density lipoprotein, SBP = systolic blood pressure.
combinations after 52 weeks ($-0.11 [−0.18, −0.04]; P < .00001) and after 104 weeks ($-0.16 [−0.21, −0.08]; P < .00001) of treatment. However, there was no significant difference between the groups in reducing percent HbA1c at week 24 of treatment period (Fig. 2; Table 4).

The SGLT2 inhibitors as add-on to metformin treatment were also found significantly ($P < .00001$) better in comparison with non-SGLT2 combinations in reducing FPG levels ($-0.65 [−0.94, −0.35]$ after 52 weeks and $-0.72 [−0.86, −0.58]$ after 104 weeks) as well as blood pressure (SBP: $-4.88 [−5.66, −4.10]$...
after 52 weeks and \(-5.33 [-6.29, -4.36]\) after 104 weeks; DBP: \(-2.38 [-2.93, -1.84]\) after 52 weeks and \(-2.55 [-3.19, -1.91]\) after 104 weeks). These improvements were also associated with significantly higher eGFR with the SGLT2 inhibitor treatment at weeks 24 and 52 but not at week 104 (Table 4).

The SGLT2 inhibitors as add-on to metformin treatment significantly (\(P < .00001\)) reduced body weight in comparison with non-SGLT2 combinations after 52 weeks (\(-3.87 [-4.94, -2.80]\)) and after 104 weeks (\(-3.53 [-4.86, -2.21]\); Fig. 3). This reduction in body weight by the SGLT2 inhibitors was associated with significant reductions in fat mass (both SAT and VAT) as well as lean mass (Fig. 4).

The safety profile of the SGLT2 inhibitors and non-SGLT2 combinations differed with respect to the incidence of genital tract infections and hypoglycemic events. The incidence of suspected or confirmed genital tract infection was significantly (\(P < .00001\)) higher in SGLT2 inhibitors treated patients (OR 6.41 [3.58, 11.45] for men and 5.12 [3.48, 7.54] for women; Fig. 5A) whereas the incidence of hypoglycemic events was significantly lower in the SGLT2 inhibitor group than in non-SGLT2 combination group (OR 0.27 [0.09, 0.78]; \(P = .02\); Fig. 5B). There was no significant difference in the incidence of urinary tract infections between both the groups (OR 1.13 [0.92, 1.39]; \(P = .25\)).

There was also no significant difference in the incidence of adverse effects in categorical measures including “at least 1 AE” (OR 1.01 [0.87, 1.16]; \(P = .94\)), “at least 1 drug-related AE” (OR 1.09 [0.81, 1.47]; \(P = .58\)) “at least 1 serious AE” (OR 0.82 [0.55, 1.22]; \(P = .33\)) or “at least 1 AE causing discontinuation” (OR 1.19 [0.91, 1.55]; \(P = .71\)). There were also no significant differences between the groups in the incidence of individual adverse effects including back pain, influenza, nausea, diarrhea, arthralgia, postural dizziness, bronchitis, gastroenteritis, constipation, nasopharyngitis, respiratory tract infection, hyperglycemia, hypertension, pollakiuria, polyuria, and orthostatic hypotension. No AE related to ketoacidosis was reported by any of the included studies.

4. Discussion

This systematic review was conducted with the aim to evaluate the long-term efficacy and safety of SGLT2 inhibitors as add-on to metformin treatment in type 2 diabetes patients. As add-on to metformin, SGLT2 inhibitor treatment was significantly better than non-SGLT2 combinations in reducing percent % HbA1c, FPG levels, body weight, and blood pressure for more than 2 years. Whereas, the incidence of hypoglycemic events was significantly lower, the incidence of suspected or confirmed genital tract infections was significantly higher in the SGLT2 inhibitor group.

Placebo-controlled trials evaluating the efficacy and safety of SGLT2 inhibitors as add-on to metformin in 52- and 104-week trials have also reported SGLT2 inhibitors to be significantly more efficacious.[20,30] Other related studies also support these findings, for example, Schernthaner et al[17] who compared CANA (300mg) with sitagliptin (100mg) as add-on to metformin plus sulfonylurea treatment in type 2 diabetes patients in 1-year duration trial, found CANA similar to sitagliptin in reducing HbA1c but CANA-treated group exhibited greater reductions in FPG, BW, and SBP. Tolerability profile of both the arms was also much similar.

These results suggest that combination therapies with metformin and SGLT2 inhibitors can provide long-term benefits to patients having inadequate control on disease with metformin. Management of type 2 diabetes with SGLT2 inhibitors is a therapeutic option which offers multiple benefits including insulin-independent mechanism of action, significant weight reduction, and blood pressure improvement besides glycemic...
control. Insulin independent mechanism of action of the SGLT2 inhibitors also makes them an attractive option in clinical practice because of their low risk of the incidence of hypoglycemia which makes it feasible to use with insulin secretagogues or early insulin therapy.

Weight loss is an important effect of the SGLT2 inhibitor therapy. Although, SGLT2 inhibitor-metformin fixed-dose bitherapeutic regimens are already in use,[31,32] future studies are needed to evaluate the evidence of efficacy and safety of these fixed-dose therapies in the longer run. The SGLT2 inhibitors are potentially better in declining body weight in comparison with its contemporary drugs. One gram of urinary glucose loss means a loss of 4 kcal energy which can lead to significant weight loss in the long run,[33] especially if lifestyle interventions are observed optimally by the patient. However, future research designs should make provisions for food and fluid intake control along with 24-hour measurement of urinary glucose excretion in the clinical trials in order to understand the mechanism of weight loss by SGLT inhibitors.[9]

Although, none of the included studies of this meta-analysis reported any case of ketoacidosis, recently FDA has warned about the production of excessive ketoacids in some diabetes patients taking SGLT2 inhibitors when it was noted that 20 cases required hospitalization owing to the acidosis with SGLT2 treatment.[34] In the present meta-analysis, SGLT2 as add-on to metformin treatment has also been found to be associated with decrease in lean mass along with fat mass. Whether the decrease in lean mass will have a significant association with ketoacidosis remains to be further researched.

The slightly higher incidence of urogenital infections in SGLT2 inhibitor treated type 2 diabetes patients has been reported after analysis of pooled data from phase III trials of over 52 weeks’ duration[35] which is thought to be due to increased urinary glucose which may act as a potential fungal growth factor in SGLT2 inhibitor treated patients.[36] In the present study, we have noted a significantly higher incidence of suspected or confirmed genital infections with almost double incidence in women than in men. Such observations have raised concerns
about the safety testing of SGLT2 inhibitors with regards to the higher incidence of genital infections.[37,38] One important limitation of this meta-analysis is that trials evaluating the efficacy of SGLT2 inhibitors beyond 2 years are not yet available. Parallel to efficacy, safety analysis in longer-term trials is also necessary. Another constraint was related to statistical heterogeneity ($I^2$) which was high in many analyses. Although, $I^2$ does not indicate variation in the effect size, nevertheless it pertains to the extent of inconsistency of findings across studies meta-analyzed in terms of the extent to which confidence intervals of the effect size of included studies overlap. To which this heterogeneity can be attributed to clinical and/or methodological heterogeneity could be clarified in future trials. Nevertheless, despite some limitations, the present analysis provides reliable summary estimates of the interventions of 6 important RCTs. As Bailey[39] postulated that keeping in mind that type 2 diabetes is a progressive disease, the need for additional therapeutic agents over time is normative and clinical experience and pertinent clinical trial outcomes can help in individualizing the therapy by patient and medication characteristics.

5. Conclusion
Sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment for type 2 diabetes mellitus patients are found significantly more efficacious than non-SGLT2 combinations in the long-term treatment duration trials by virtue of their effects in improving disease markers (% HbA1c and FPG levels), blood pressure, and body weight. Incidence of hypoglycemic events was significantly lower but incidence of genital tract infections was significantly higher in patients treated with SGLT2 inhibitors. However, more trials are required to assess the efficacy and safety of SGLT2 inhibitors beyond 2 years.

References
[1] WHO. Diabetes Factsheet 2016. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed on March 11, 2017.
[2] Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011;2:133–45.
[3] Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab 2016;10:546–51.
[4] Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manage 2008;4:743–51.
[5] Scheen AJ, Paquot N. Metformin revisited: a critical review of the evidence. Vasc Health Risk Manage 2015;11:849–57.
[6] American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2015;38(Suppl):S41–8.
[7] Garber AJ, Abrahamsson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438–47.
[8] Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Prediclinal and clinical data. Pharmacol Ther 2013;139:51–9.
[9] Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of Diabetes Mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752–72.
[10] Carlson CJ, Santamaria ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf 2016;15:1401–12.
[11] Kipnes MS. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;1:145–56.
[12] Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375–93.
[13] Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289–312.
[14] List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650–7.
[15] Bailey CJ, Iqbal N, Iyon C, et al. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951–9.
[16] Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013;15:432–40.
[17] Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–15.
[18] Häring HU, Merker I, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396–404.
[19] Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147–58.
[20] Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract 2014;105:313–21.
[21] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.
[22] Celano WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941–50.
[23] Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release glimepiride formulation. Diabetes Res Clin Pract 2016;112:50–6.
[24] DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384–93.
[25] Ferrannini E, Berk A, Hanot S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015–21.
[26] Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia 2013;56:2582–92.
[27] Naukk MA, Del Prato S, Moier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015–22.
[28] Naukk MA, Baranov O, Ritzel RA, et al. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013;56:1878–83.
[29] Riddervold M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691–700.
[30] Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43.
[31] Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination. Diabetes Metab Syndr Obes 2015;8:287–94.
[32] Kula L. Invokamet (Canagliflozin plus Metformin HCl): First fixed-dose combination with an sgl2 inhibitor approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 2015;8:70–4.
[33] Jabbour SA, Whaley JM, Tirmenstein M, et al. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med 2012;124:62–73.
[34] US Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed May 9, 2016.

[35] Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7–17.

[36] Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962–71.

[37] Doggrella S, McIntyre K. Canagliflozin—something new for type 2 diabetes, but is it safe and efficacious? Expert Opin Pharmacother 2014;15:437–41.

[38] Davis SN. Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert Rev Clin Pharmacol 2014;7:21–3.

[39] Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013;126:S10–20.